Clinical pharmacokinetics and pharmacodynamics of ongericimab: A potential long‐acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: Randomized, double‐blind, placebo‐controlled phase Ia and Ib/II studies

Ejemplares similares

• Safety, pharmacokinetics, and pharmacodynamics of anti‐IL‐4Rα antibody SHR‐1819 in healthy subjects: A randomized, controlled phase I study
  por: Na Li, et al.
  Publicado: (2024)
• Safety, pharmacokinetics, and pharmacodynamics of ART‐648, a PDE4 inhibitor in healthy subjects: A randomized, placebo‐controlled phase I study
  por: Akira Tanaka, et al.
  Publicado: (2024)
• Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK‐001 using a randomized, double‐blind, placebo‐controlled study design
  por: Sibel Ucpinar, et al.
  Publicado: (2024)
• Correction to “Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl‐tRNA synthetase inhibitor, in healthy subjects”
  Publicado: (2024)
• Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non‐covalent BTK inhibitor, in healthy subjects: First‐in‐human phase I study
  por: Kyoko Miyamoto, et al.
  Publicado: (2024)